3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomatitis
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Stroke
1
Nasopharyngeal Neoplasms
1
Myocardial Infarction
1
Mesothelioma
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Transitional Cell
1
Anemia
1
Interventions
toripalimab
4
pembrolizumab
4
Gemcitabine
4
tislelizumab
2
durvalumab
2
Nivolumab
2
Cisplatin
2
Carboplatin
2
AZD4547
2
tipifarnib
1
tesetaxel
1
sapanisertib
1
regorafenib
1
pyrotinib
1
nintedanib
1
famitinib
1
disitamab vedotin
1
camrelizumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
anlotinib
1
aldesleukin
1
advexin
1
Vitamin B 12
1
Trastuzumab
1
Taxes
1
Surgical Procedures, Operative
1
Saline Solution
1
Resistance Training
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Transitional Cell
×
Vitamin B 12
×
Clear all
NCT03193788
2017-06-21
PREMIER
Asan Medical Center
Phase 3
Unknown
74 enrolled